Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | PPARD | Q03181 | 7/20 | 0.55 |
| ▸ | PPARA | Q07869 | 7/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | FABP4 | P15090 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248269 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL249583 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL251208 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL3406713 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL342408 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL251332 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL227302 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL200185 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL251008 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL147806 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129397-B1 | PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | SANOFI SA (FR) | 2019-01-09 | — | — | EP | claimed |
| EP-3129395-B1 | EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS | SANOFI SA (FR) | 2018-12-19 | — | — | EP | claimed |
| US-9775904-B2 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists | SANOFI (FR) | 2017-10-03 | — | — | US | claimed |
| US-9771406-B2 | Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 | SANOFI (FR) | 2017-09-26 | — | — | US | claimed |
| US-9758561-B2 | Dual GLP-1/glucagon receptor agonists derived from exendin-4 | SANOFI (FR) | 2017-09-12 | — | — | US | claimed |
| US-9760032-B1 | Toner composition and process | XEROX CORPORATION (US) | 2017-09-12 | — | — | US | claimed |
| US-20170248859-A1 | TONER COMPOSITION AND PROCESS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2017-08-31 | — | — | US | claimed |
| EP-3129397-A1 | PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | Sanofi (FR) | 2017-02-15 | — | — | EP | claimed |
| EP-3129395-A1 | EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS | Sanofi (FR) | 2017-02-15 | — | — | EP | claimed |
| EP-3129396-A1 | DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | Sanofi (FR) | 2017-02-15 | — | — | EP | claimed |
| WO-2015155140-A1 | DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | SANOFI (FR) | 2015-10-15 | — | — | WO | claimed |
| US-20150168861-A1 | TONER ADDITIVES FOR IMPROVED CHARGING | XEROX CORPORATION (US) | 2015-06-18 | — | — | US | claimed |
| EP-1975729-B1 | Tonerprocesses | XEROX CORP (US) | 2010-11-10 | — | — | EP | claimed |
| US-7749673-B2 | Toner processes | XEROX CORPORATION (US) | 2010-07-06 | — | — | US | claimed |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2009-08-13 | — | — | US | claimed |
| US-20080236446-A1 | Toner processes | XEROX CORPORATION | 2008-10-02 | — | — | US | claimed |
| EP-1975729-A1 | Tonerprocesses | Xerox Corporation (US) | 2008-10-01 | — | — | EP | claimed |
| CN-101222942-A | Peptides for use in the treatment of obesity | NOVO NORDISK AS (DK) | 2008-07-16 | — | — | CN | claimed |
| EP-1907010-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2008-04-09 | — | — | EP | claimed |
| WO-2007009894-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | MC4R, MC3R, GIPR | TSHR 145/4885LMNA 4302/4885NFKB1 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.